全球心血管支架市场－2025-2030年预测

预计心血管支架市场将从 2025 年的 129.13 亿美元成长到 2030 年的 180.18 亿美元，复合年增长率为 6.89%。

由于心血管疾病盛行率不断上升以及人口老化导致冠状动脉阻塞患者需要接受治疗，全球心血管支架市场预计将持续成长。这些支架能够恢復狭窄或阻塞动脉的血流，透过降低心臟病发作和中风的风险来改善患者的生活品质。然而，支架植入后血栓形成的风险以及搭桥手术等替代治疗方法的存在，是限制市场扩张的主要阻碍因素。

市场驱动因素

心血管疾病盛行率不断上升

心血管疾病是全球首要死因，其发生率的快速成长是推动心血管支架需求成长的主要因素。世界卫生组织（世卫组织）的报告显示，心血管疾病占全球每年死亡人数的32%，相当于约1,790万人死亡。美国疾病管制与预防中心（CDC）指出，心臟相关疾病每年导致65.5万人死亡。此外，在澳大利亚，心血管疾病影响超过400万人，每天夺走118人的生命。压力、不良饮食和久坐的职场环境等生活方式因素会加剧这些疾病，增加动脉阻塞，从而推动对用于恢復血流的支架的需求。随着心血管疾病发病率的持续上升，预计到2030年，这一趋势将推动市场成长。

人口老化加剧

人口老化是推动市场发展的主要因素，因为老年人更容易患上心血管疾病，而这些疾病需要支架来有效管理血流。根据联合国估计，到2050年，65岁及以上人口的比例预计将达到15%，高于2020年的9.5%。这种人口结构变化正在推动对支架的需求，因为与老龄化相关的动脉功能下降需要干预以维持心血管健康，这显着促进了支架市场的扩张。

市场限制

血栓风险和替代疗法

支架植入术后血栓形成的风险是其主要限制之一。血栓阻塞血流，增加心肌梗塞和中风的风险。研究表明，1-2%的支架植入患者会出现血栓，尤其是在术后最初几个月。儘管采取了预防措施，这种风险仍会长期存在。此外，诸如搭桥手术等替代治疗方法也阻碍了支架市场的成长。对于多处动脉阻塞的患者，由于搭桥手术血栓风险较低且长期疗效较佳，因此通常建议使用搭桥手术而非支架植入术。美国心臟学会的研究显示，接受支架植入术的患者10年内死亡率为29.87%，而接受搭桥手术的患者死亡率为24.7%。主要死因是血栓引起的中风或心肌梗塞。此外，接受支架手术的患者中有 16.1% 需要再次手术，而接受搭桥手术的患者中只有 8% 需要再次手术，这表明搭桥手术的疗效更佳。

市场展望

受心血管疾病盛行率上升和人口老化的影响，心血管支架市场预计将在2030年前持续成长。然而，血栓风险以及搭桥手术的竞争要求支架技术不断进步，以提高其安全性和有效性。相关人员必须专注于创新，以应对这些挑战，并满足市场对微创心血管治疗方案日益增长的需求。

本报告的主要优势：

• 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
• 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
• 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
• 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
• 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

• 历史资料（2022-2024 年）和预测资料（2025-2030 年）
• 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
• 竞争对手定位、策略和市场占有率分析
• 按业务板块和地区（国家）分類的收入成长和预测分析
• 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

• 市场概览
• 市场定义
• 分析范围
• 市场区隔

第三章 商业情境

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策和法规
• 策略建议

第四章 技术展望

5. 全球心血管支架市场（按类型划分）

• 介绍
• 双效支架
• 裸金属支架
• 药物释放型支架
• 其他的

6. 全球心血管支架市场（依材料划分）

• 介绍
• 聚合物
• 金属
  • 不銹钢
  • 钴铬
  • 其他的

7. 全球心血管支架市场（依最终用户划分）

• 介绍
• 医院
• 门诊手术中心
• 其他的

8. 全球心血管支架市场（依地区划分）

• 介绍
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 以色列
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 台湾
  • 其他的

第九章 竞争格局与分析

• 主要企业和策略分析
• 市占率分析
• 企业合併、协议、商业合作
• 竞争对手仪錶板

第十章：公司简介

• Abbott Laboratories
• Medtronic
• Boston Scientific Corporation
• B. Braun
• Terumo Corporation
• BIOTRONIK SE & Co. KG
• MicroPort Scientific Corporation
• Translumina
• Integer Holdings Corporation
• HEXACATH

第十一章附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要收益
• 分析方法
• 简称

The Cardiovascular Stent Market is projected to rise from USD 12.913 billion in 2025 to USD 18.018 billion in 2030, driven by a 6.89% compound annual growth rate (CAGR).

The global cardiovascular stent market is poised for growth, driven by the rising prevalence of cardiovascular diseases and an aging population requiring interventions for coronary artery blockages. These stents restore blood flow in narrowed or blocked arteries, reducing risks of heart attacks and strokes, thereby improving patient quality of life. However, challenges such as the risk of blood clot formation post-stent placement and the availability of alternative treatments like bypass surgery pose significant constraints to market expansion.

Market Drivers

Rising Cardiovascular Disease Prevalence

The surge in cardiovascular diseases, the leading global cause of death, significantly drives demand for cardiovascular stents. The World Health Organization reports that these diseases account for 32% of annual deaths worldwide, equating to approximately 17.9 million fatalities. In the United States, the Centers for Disease Control and Prevention note that 655,000 deaths occur annually due to heart-related issues, while in Australia, cardiovascular conditions affect over 4 million people, claiming 118 lives daily. Lifestyle factors, including stress, poor dietary habits, and sedentary work cultures, exacerbate these conditions, increasing artery blockages and the need for stents to restore blood flow. This trend is expected to fuel market growth through 2030 as the incidence of cardiovascular issues continues to rise.

Growing Geriatric Population

The expanding geriatric demographic is a key market driver, as older individuals are more prone to cardiovascular conditions requiring stents for effective blood flow management. The United Nations projects that the global population aged 65 and above will reach 15% by 2050, up from 9.5% in 2020. This demographic shift heightens the demand for stents, as age-related artery failures necessitate interventions to maintain cardiovascular health, significantly contributing to market expansion.

Market Constraints

Risk of Blood Clots and Alternative Treatments

A major limitation is the risk of blood clot formation post-stent implantation, which can disrupt blood flow and elevate the risk of heart attacks or strokes. Research indicates that 1-2% of stent recipients develop clots, particularly in the initial months post-procedure, with risks persisting long-term despite preventive measures. Additionally, alternative treatments like bypass surgery challenge market growth. For patients with multiple artery blockages, bypass surgery is often recommended over stents due to lower clot risks and better long-term outcomes. A study by the American College of Cardiology found that 29.87% of stent patients died within 10 years compared to 24.7% of bypass surgery patients, with stroke or heart attack due to clots as the primary cause. Furthermore, 16.1% of stent patients required a second procedure, compared to 8% for bypass patients, highlighting bypass surgery's superior efficacy.

Market Outlook

The cardiovascular stent market is set to grow through 2030, driven by increasing cardiovascular disease prevalence and an aging population. However, the risk of clots and competition from bypass surgery necessitate advancements in stent technology to enhance safety and efficacy. Stakeholders must focus on innovation to address these challenges and capitalize on the growing demand for minimally invasive cardiovascular solutions.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Market Segmentation:

By Type

• Dual Therapy Stent
• Bare Metal Stent
• Drug Eluting Stent
• Others

By Material

• Polymers
• Metal
• Stainless Steel
• Cobalt Chromium
• Others

By End-User

• Hospitals
• Ambulatory Surgical Centers
• Others

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL CARDIOVASCULAR STENT MARKET BY TYPE

• 5.1. Introduction
• 5.2. Dual Therapy Stent
• 5.3. Bare Metal Stent
• 5.4. Drug Eluting Stent
• 5.5. Others

6. GLOBAL CARDIOVASCULAR STENT MARKET BY MATERIAL

• 6.1. Introduction
• 6.2. Polymers
• 6.3. Metal
  • 6.3.1. Stainless Steel
  • 6.3.2. Cobalt Chromium
  • 6.3.3. Others

7. GLOBAL CARDIOVASCULAR STENT MARKET BY END-USER

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Ambulatory Surgical Centers
• 7.4. Others

8. GLOBAL CARDIOVASCULAR STENT MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Israel
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Taiwan
  • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Abbott Laboratories
• 10.2. Medtronic
• 10.3. Boston Scientific Corporation
• 10.4. B. Braun
• 10.5. Terumo Corporation
• 10.6. BIOTRONIK SE & Co. KG
• 10.7. MicroPort Scientific Corporation
• 10.8. Translumina
• 10.9. Integer Holdings Corporation
• 10.10. HEXACATH

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key benefits for the stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations